Ingilterra -
Ingliż -
MHRA (Medicines & Healthcare Products Regulatory Agency)
perjeta 420mg14ml concentrate for solution for infusion vials
roche products ltd - pertuzumab - solution for infusion - 30mg/1ml
Ingilterra -
Ingliż -
MHRA (Medicines & Healthcare Products Regulatory Agency)
gazyvaro 1000mg40ml concentrate for solution for infusion vials
roche products ltd - obinutuzumab - solution for infusion - 25mg/1ml
Armenja -
Ingliż -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
gazyva 1000mg/40ml concentrate for solution for infusion
f. hoffmann-la roche ltd. 4303 kaiseraugst- batch releaser - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml
Armenja -
Ingliż -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
perjeta concentrate for solution for infusion
roche diagnostics gmbh - pertuzumab - concentrate for solution for infusion - 30mg/ml
Armenja -
Ingliż -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
gazyva concentrate for solution for infusion
f. hoffmann-la roche ltd. 4303 kaiseraugs- secondary packager - obinutuzumab - concentrate for solution for infusion - 1000mg/40ml
Armenja -
Ingliż -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
perjeta concentrate for solution for infusion
f. hoffmann-la roche ltd. - pertuzumab - concentrate for solution for infusion - 30mg/ml
New Zealand -
Ingliż -
Medsafe (Medicines Safety Authority)
phesgo
roche products (nz) ltd - pertuzumab 80 mg/ml; trastuzumab 40 mg/ml; - solution for injection - active: pertuzumab 80 mg/ml trastuzumab 40 mg/ml excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
New Zealand -
Ingliż -
Medsafe (Medicines Safety Authority)
phesgo
roche products (nz) ltd - pertuzumab 60 mg/ml; trastuzumab 60 mg/ml; - solution for injection - active: pertuzumab 60 mg/ml trastuzumab 60 mg/ml excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 sucrose trehalose dihydrate water for injection - early breast cancer phesgo is indicated in combination with chemotherapy for: - neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either >2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. - adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence. metastatic breast cancer phesgo is indicated in combination with docetaxel for patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
Panama -
Ingliż -
Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)
perjeta 420 mg / 14 ml concentrado para solucion para infusion intravenosa
f. hoffmann-la roche s.a. - pertuzumab - pertuzumab....420 mg
Panama -
Ingliż -
Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)
gazyva 1000 mg /40 ml concentrado para solucion para infusión i.v.
f. hoffmann la roche s.a. - obinutuzumab - obinutuzumab....1000 mg